Beckman Coulter Life Sciences is taking actions in the best interests of our associates, customers, and business partners as we navigate the growing threats of the 2019 Novel Coronavirus disease (COVID-19).Learn more
Beckman.com will be conducting maintenance on its infrastructure Friday, May 7th thru Sunday, May 9th. During this time, MyBeckman account registration, login functionality and accessing features such as the shopping cart may have delays across the site. If you need assistance accessing your account or placing orders, please contact Client Services.
What are some of the ways CRISPR can enhance improved therapeutic agents?
Combining CRISPR with conventional pharmaceutical agents can be more effective than using the traditional therapeutic options by themselves. CRISPR has rapidly accelerated drug discovery, identification, and preclinical validation, whether by modifying cells to mimic human pathophysiological conditions, generating screens, or developing transgenic animal models. CRISPR-based immunotherapeutics is being tested for the treatment of cancers, as well as a variety of genetically predisposed conditions including sickle cell anemia. With advances in genome sequencing, it is conceivable to envision a customized treatment plan where DNA-editing drugs are prescribed to a patient to target genome sequencing-revealed mutations. For more information on CRISPR visit our resource center here.
Oops. The page you wanted could not be found, so we brought you to something similar. If you still can't find what you want, try searching our site instead.